Novo Nordisk A/S (NVO): Today's Featured Drugs Laggard

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.

Novo Nordisk A/S ( NVO) pushed the Drugs industry lower today making it today's featured Drugs laggard. The industry as a whole closed the day up 0.4%. By the end of trading, Novo Nordisk A/S fell $2.11 (-1.3%) to $158.18 on average volume. Throughout the day, 356,355 shares of Novo Nordisk A/S exchanged hands as compared to its average daily volume of 318,800 shares. The stock ranged in price between $157.17-$158.98 after having opened the day at $158.84 as compared to the previous trading day's close of $160.29. Other companies within the Drugs industry that declined today were: Pain Therapeutics ( PTIE), down 36.6%, Durect Corporation ( DRRX), down 33.6%, Biocryst Pharmaceuticals ( BCRX), down 12.4%, and Idera Pharmaceuticals ( IDRA), down 12.3%.
  • EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

Novo Nordisk A/S, a healthcare company, engages in the discovery, development, manufacture, and marketing of pharmaceutical products in Denmark and internationally. The company operates in two segments, Diabetes Care and Biopharmaceuticals. Novo Nordisk A/S has a market cap of $93.55 billion and is part of the health care sector. The company has a P/E ratio of four, below the S&P 500 P/E ratio of 17.7. Shares are up 39.9% year to date as of the close of trading on Wednesday. Currently there are two analysts that rate Novo Nordisk A/S a buy, one analyst rates it a sell, and two rate it a hold.

TheStreet Ratings rates Novo Nordisk A/S as a buy. The company's strengths can be seen in multiple areas, such as its growth in earnings per share, increase in net income, notable return on equity, expanding profit margins and good cash flow from operations. We feel these strengths outweigh the fact that the company is trading at a premium valuation based on our review of its current price compared to such things as earnings and book value.

On the positive front, Novogen ( NVGN), up 32.7%, Prestige Brands Holdings ( PBH), up 18.5%, Savient Pharmaceuticals ( SVNT), up 17.9%, and China Pharma ( CPHI), up 13.5%, were all gainers within the drugs industry with Teva Pharmaceutical Industries ( TEVA) being today's featured drugs industry leader.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

FREE for a limited time only: Get TheStreet Ratings #1 Stock Report NOW!.
null

If you liked this article you might like

Novo Nordisk Shares Leap Higher After Solid Earnings and Full-Year Sales Upgrade

Nevada Senate Passes Bill to Force Diabetes Drug Manufacturers to Disclose Pricing Practices

Dow Holds Lower After House Passes Health Care Vote, Crude Falls

Daily Earnings Round-Up

5 Things You Must Know Before the Market Opens Wednesday